PMID- 37305548
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230613
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - The efficacy and safety of Trilaciclib in preventing chemotherapy-induced 
      myelosuppression: a systematic review and meta-analysis of randomized controlled 
      trials.
PG  - 1157251
LID - 10.3389/fphar.2023.1157251 [doi]
LID - 1157251
AB  - Background: This study aims to assess the clinical efficacy and safety of 
      Trilaciclib in preventing chemotherapy-induced myelosuppression in adult patients 
      through meta-analysis. Methods: The PubMed, Embase, Cochrane Library, Clinical 
      Trials, EU Clinical Trials Register, and International Clinical Trials Registry 
      Platform were searched up to 25 October 2022. Only randomized controlled trials 
      (RCTs) comparing the clinical outcomes of Trilaciclib and Trilaciclib plus 
      chemotherapy for treating malignant cancers in adult patients were included. The 
      primary outcome included the incidence of SN, FN, the DSN, and administration of 
      ESAs, G-CSFs, and RBC or platelet transfusions, while the secondary outcomes 
      included the risk of adverse events (AEs) and severe adverse events (SAEs). 
      Results: In total, four randomized controlled trials (RCTs) involving 345 
      patients with SCLC or breast cancer were included in this meta-analysis. Results 
      showed that administration of Trilaciclib significantly reduced the occurrence of 
      SN (19.3% vs. 42.2%, OR = 0.31), FN (3.22% vs. 6.72%, OR = 0.47), anemia (20.5% 
      vs. 38.2%, OR = 0.38) and shortened the DSN during treatment. The proportion of 
      patients receiving therapeutic use of ESAs (4.03% vs. 11.8%, OR = 0.31), G-CSF 
      (37.0% vs. 53.5%, OR = 0.52), RBC transfusions (19.8% vs. 29.9%, OR = 0.56) was 
      also statistically lower in the experimental group than in the control group. 
      Meanwhile, the ORR, overall survival, and progress-free survival of the two 
      groups were identical, and no negative impact of Trilaciclib on the clinical 
      outcomes of chemotherapy treatments was found. Other chemotherapy-induced adverse 
      events (AEs) and severe adverse events (SAEs) like diarrhea, fatigue, nausea, and 
      vomiting were identical regardless of Trilaciclib usage. Conclusion: Trilaciclib 
      demonstrated its efficacy in reducing the occurrence of chemotherapy-induced 
      myelosuppression and utilization of supportive care interventions without 
      undermining the clinical benefits of chemotherapy regimens during treatment with 
      an acceptable safety profile.
CI  - Copyright (c) 2023 Qiu, Sheng, Lin, Jiang and Shi.
FAU - Qiu, Jingyue
AU  - Qiu J
AD  - Pharmaceutical Department, PLA Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Sheng, Dandan
AU  - Sheng D
AD  - Pharmaceutical Department, PLA Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Lin, Fei
AU  - Lin F
AD  - Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, 
      Chengdu, China.
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, China.
FAU - Jiang, Peng
AU  - Jiang P
AD  - Medical Team, PLA Strategic Support Force Integrated Training Team, Beijing, 
      China.
FAU - Shi, Ning
AU  - Shi N
AD  - Pharmaceutical Department, PLA Strategic Support Force Medical Center, Beijing, 
      China.
LA  - eng
PT  - Systematic Review
DEP - 20230525
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10248018
OTO - NOTNLM
OT  - CDK4/6 inhibitor
OT  - chemotherapy
OT  - meta-analysis
OT  - myelosuppression
OT  - trilaciclib
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/12 06:42
MHDA- 2023/06/12 06:43
PMCR- 2023/05/25
CRDT- 2023/06/12 04:25
PHST- 2023/02/02 00:00 [received]
PHST- 2023/05/17 00:00 [accepted]
PHST- 2023/06/12 06:43 [medline]
PHST- 2023/06/12 06:42 [pubmed]
PHST- 2023/06/12 04:25 [entrez]
PHST- 2023/05/25 00:00 [pmc-release]
AID - 1157251 [pii]
AID - 10.3389/fphar.2023.1157251 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 May 25;14:1157251. doi: 10.3389/fphar.2023.1157251. 
      eCollection 2023.